Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Obstet Gynaecol Res ; 44(10): 2003-2007, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30043438

ABSTRACT

Recent reports showed that neoadjuvant chemotherapy (NAC) has been successfully applied to treat advanced uterine cervical cancers during pregnancy. However, its side effects on the fetus remain unclear. Here, we report a 33-year-old primipara who underwent four courses of NAC therapy, paclitaxel and cisplatin, from 17 to 27 weeks of gestation due to uterine cervical cancer stage IB2. At 31 weeks of gestation, cesarean section and radical hysterectomy were performed, and a female baby weighing 1446 g was born. Although pre- and postnatal courses were uneventful, neonatal erythroderma over the entire body was observed just after delivery. The pathological diagnosis was ichthyosiform erythroderma, which was later demonstrated to be keratitis-ichthyosis-deafness syndrome, by exome sequencing analysis. Although her skin disorder was consistent with keratitis-ichthyosis-deafness syndrome, the skin condition gradually improved after delivery. These findings suggest that NAC therapy during pregnancy might cause or exacerbate systemic skin lesions in the fetus/neonate.


Subject(s)
Antineoplastic Agents/adverse effects , Ichthyosiform Erythroderma, Congenital/chemically induced , Keratitis/chemically induced , Pregnancy Complications, Neoplastic , Uterine Cervical Neoplasms , Adult , Cesarean Section , Chemotherapy, Adjuvant/adverse effects , Female , Humans , Hysterectomy , Infant, Newborn , Pregnancy , Pregnancy Complications, Neoplastic/drug therapy , Pregnancy Complications, Neoplastic/surgery , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...